MBX Biosciences, Inc.
MBX Biosciences, Inc. is listed today as MBX Biosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2022 | $47 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jul 2020 | $26 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
MBX Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2022).
SEC Form D · Nov 2022
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2022
That is all the official record says: MBX Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of MBX Biosciences, Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Fhmls X, L.L.C. | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Fhmls X, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Frazier Life Sciences X, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| James M. Cornelius | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2024) | SEC Form 3 |
| Nea 17 GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| NEA Partners 17, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| New Enterprise Associates 17, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| OrbiMed Capital GP VII LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| P. Kent Hawryluk | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2024) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.
Largest shareholders today
Institutions holding MBX Biosciences, Inc. shares, as of Sep 30, 2026.
- FMR LLC$432 M14.84%
- Frazier Life Sciences Management, L.P.$390 M13.40%
- Wellington Management Group LLP$303 M10.40%
- Paradigm Biocapital Advisors LP$221 M7.60%
- NEA Management Company, LLC$212 M7.28%
- BlackRock, Inc.$204 M7.00%
- Orbimed Advisors LLC$180 M6.19%
- NVP Associates, LLC$125 M4.30%
- Polar Capital Holdings Plc$94 M3.23%
- Vanguard Capital Management LLC$84 M2.88%
- Aaron Wealth Advisors LLC$69 M2.37%
- Driehaus Capital Management LLC$59 M2.04%
- Kynam Capital Management, LP$55 M1.88%
- Eventide Asset Management, LLC$51 M1.76%
- State Street Corp$51 M1.73%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Peter Kent Hawryluk | Executive officer | Nov 2022 |
| Richard Kent DiMarchi | Executive officer | Nov 2022 |
| Richard M. Bartram | Executive officer | Nov 2022 |
| Timothy Kent Knickerbocker | Executive officer | Jul 2020 |
| Carl M. Gordon | Director | Nov 2022 |
| Edward M. Mathers | Director | Nov 2022 |
| James M. Cornelius | Director | Nov 2022 |
| Ora Kent Pescovitz | Director | Nov 2022 |
| Patrick M. Heron | Director | Nov 2022 |
| Peter Kent Hawryluk | Director | Nov 2022 |
| Richard Kent DiMarchi | Director | Nov 2022 |
| Tiba M. Aynechi | Director | Nov 2022 |
| Timothy Kent Knickerbocker | Director | Jul 2020 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.